Terminated PHASE2 INTERVENTIONAL 6-arm NCT00973141

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Moderate to Severe Knee or Hip Pain From Osteoarthritis

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions Arthralgia Joint Pain Osteoarthritis Osteoarthritis, Hip Osteoarthritis, Knee Pain

Interventions JNJ-42160443 Placebo

Updated 9 times since 2017 Last updated: Mar 6, 2020 Started: Sep 16, 2009 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Logistic reasons associated with the FDA-imposed clinical hold.

Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Other Arthralgia trials with similar outcome

NCT01094262 · Phase PHASE2 · Jul 2011

Browse all Arthralgia trials

A PHASE2 clinical study on Arthralgia and Joint Pain, this trial is terminated or withdrawn. The trial is conducted by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and has accumulated 9 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Apr 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Apr 2020 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Austin, United States , Baton Rouge, United States , Bedford, United States , Bialystok, Poland , Birmingham, United States , Boise, United States , Brampton, Canada , Burnaby, Canada , Busan, South Korea and 67 more locations